Piramal pharma share price

At such a juncture, the company announced rights issue to existing shareholders of upto ₹1,050 crore. The proceeds from the rights issue will be used to repay a debt of ₹778 crores (15 per cent of outstanding net debt as of December 2022) according to the draft letter of offering filed on March 28. Equity dilution amidst weak operating environment Using (high-cost) equity to repay (low-cost) debt may prove to be returns dilutive to shareholders. Especially considering that the company is using internal accruals to fund capacity expansion to the tune of $100 million or ₹820 crore so far in 9MFY23. The current operating performance of the company is also not encouraging. The company reported revenue growth of 11 per cent YoY in 9MFY23 driven by CDMO business (56 per cent of revenue and 12 per cent YoY growth), complex hospital generics business (32 per cent contribution and 9 per cent YoY growth) and Indian consumer healthcare business (13 per cent contribution and 19 per cent YoY growth). Also read: But more importantly, EBITDA margins declined from 17 per cent in 9MFY22 to 10 per cent in 9MFY23. The company reported under utilisation of capacities as clients delayed decision-making in an uncertain macroeconomic environment. The increased headcount and operating expenses added negatively to operating leverage further impacting performance in a period with higher marketing expenses, input material cost, and negative forex impact. Following suit That said, the Piramal Pharma ...

Piramal Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Piramal Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research https://www.valueresearchonline.com/stocks/308628/piramal-pharma-ltd/ Get Piramal Pharma Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house. Business Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.

Business Description Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organisation business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India. Does PPLPHARMA pay dividends? If so, how much? No. PPLPHARMA does not currently have a forward dividend yield. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Learn more about How big is Piramal Pharma Ltd? PPLPHARMA’s market cap is 109.28 Bil. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. Learn more about How has PPLPHARMA performed historically compared to the market? PPLPHARMA’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its...

NAME P/E (x) P/B (x) ROE % ROCE % ROA % Rev CAGR [3Yr] OPM NPM Basic EPS Current Ratio Total Debt/ Equity (x) Total Debt/ CFO (x) -58.97 1.62 -2.75 1.65 -1.28 0.00 2.49 -3.40 -1.57 1.26 0.81 0.00 21.27 2.09 9.81 13.89 8.89 11.59 30.85 21.54 47.44 9.46 0.00 0.00 29.55 7.00 23.70 31.27 20.92 17.44 42.16 30.68 16.16 6.37 0.04 0.00 35.11 2.75 7.82 9.58 5.53 6.97 7.70 6.59 17.40 1.78 0.15 0.00 16.31 2.39 14.67 17.61 12.64 11.49 32.37 26.42 39.18 4.39 0.03 0.00 Add More About Piramal Pharma Piramal Pharma Ltd., incorporated in the year 2020, is a Small Cap company (having a market cap of Rs 10,996.43 Crore) operating in Pharmaceuticals sector. Piramal Pharma Ltd. key Products/Revenue Segments include Sale of Products, Sale of services and Other Operating Revenue for the year ending 31-Mar-2022. For the quarter ended 31-03-2023, the company has reported a Consolidated Total Income of Rs 2,188.08 Crore, up 21.66 % from last quarter Total Income of Rs 1,798.51 Crore and down .97 % from last year same quarter Total Income of Rs 2,209.50 Crore. Company has reported net profit after tax of Rs 42.33 Crore in latest quarter. The company’s top management includes Mrs.Nandini Piramal, Mr.Vivek Valsaraj, Mr.Peter DeYoung, Mr.Nathalie Leitch, Mr.Neeraj Bharadwaj, Mr.Jairaj Purandare, Mr.Peter Stevenson, Mr.S Ramadorai, Mr.Sridhar Gorthi, Ms.Vibha Paul Rishi, Mr.Tanya Sanish. Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-03-2023, the company has a total of 119.33 Crore s...

Sales 2023 69704M 851M 851M Net income 2023 -1899M -23,2M -23,2M Net Debt 2023 37863M 462M 462M P/E ratio 2023 -91,2x Yield 2023 - Sales 2024 79456M 970M 970M Net income 2024 1632M 19,9M 19,9M Net Debt 2024 35800M 437M 437M P/E ratio 2024 66,3x Yield 2024 0,88% Capitalization 110B 1342M 1342M EV / Sales 2023 2,12x EV / Sales 2024 1,83x Nbr of Employees - Free-Float 43,3% More Financials Company Piramal Pharma Limited is an India-based company, which offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities. The Company has approximately 15 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal...

Bole Toh? 1. Is Piramal Pharma Ltd a good quality company? Past below average quality company. 2. Is Piramal Pharma Ltd undervalued or overvalued? The Fair zone. 3. Is Piramal Pharma Ltd a good buy now? The Strong which suggest that the price of Piramal Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing Value Creation ⓘ Value Creation Index Colour Code Guide ⓘ Mar'21 Mar'22 TTM ROCE % ⓘ 12.8% 7% - Value Creation Index ⓘ -0.1 -0.5 - Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ Sales ⓘ 2,939 3,095 3,443 YoY Gr. Rt. % - 5.3% - Adj EPS ⓘ 5.5 2.8 0.6 YoY Gr. Rt. % - -49.5% - BVPS (₹) ⓘ 41.2 42.7 44.1 Adj Net Profit ⓘ 544 327 69 Cash Flow from Ops. ⓘ 34.7 255 - Debt/CF from Ops. ⓘ 4.8 4.3 -

Piramal Pharma Limited is an India-based company, which offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities. The Company has approximately 15 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other therapies.;